To discuss the regulatory challenges surrounding the use of injectable peptides for muscle growth, recovery, and antiaging, particularly in the context of social media influence, including the implications of regulatory fragmentation.
Approach:
Key Findings:
Peptides are being promoted online outside conventional pharmaceutical channels.
The regulatory frameworks are fragmented and struggle to keep pace with the evolving market.
There is limited human data on the safety and efficacy of many peptides used for enhancement, with potential risks such as pathologic angiogenesis and toxic metabolites.
Younger populations are more aware of and influenced by peptide use due to social media.
The overlap between therapeutic and enhancement uses of peptides complicates regulatory distinctions.
Interpretation:
The authors argue that the current regulatory environment is insufficient to address the complexities of peptide use, particularly as many users may not recognize their behavior as substance use, highlighting the structural friction and the role of digital ecosystems.
Limitations:
Research on illicit peptide use is sparse, despite the relative ease of studying these compounds.
Existing surveillance systems are not designed to capture emerging harms related to peptide use.
Conclusion:
Without adaptive, system-oriented responses, drug policy will remain reactive and inadequate for the evolving peptide marketplace.
Interviews with hospital leaders and employed physicians highlighted financial pressures, perceived care-integration benefits, and unresolved operational tensions following acquisition.
